Resverlogix Corp. (RVX.TO)

CAD 0.06

(0.0%)

Total Debt Summary of Resverlogix Corp.

  • Resverlogix Corp.'s latest annual total debt in 2022 was 6.49 Million USD , down -7.8% from previous year.
  • Resverlogix Corp.'s latest quarterly total debt in 2023 Q2 was 6.84 Million USD , down 0.0% from previous quarter.
  • Resverlogix Corp. reported annual total debt of 7.04 Million USD in 2021, down 0.0% from previous year.
  • Resverlogix Corp. reported annual total debt of - USD in 2020, down -100.0% from previous year.
  • Resverlogix Corp. reported quarterly total debt of 6.84 Million USD for 2023 Q2, down 0.0% from previous quarter.
  • Resverlogix Corp. reported quarterly total debt of 6.77 Million USD for 2023 Q3, down -1.11% from previous quarter.

Annual Total Debt Chart of Resverlogix Corp. (2022 - 2001)

Historical Annual Total Debt of Resverlogix Corp. (2022 - 2001)

Year Total Debt Total Debt Growth
2022 6.49 Million USD -7.8%
2021 7.04 Million USD 0.0%
2020 - USD -100.0%
2019 13.15 Million USD -10.95%
2018 14.77 Million USD 1986.58%
2017 708 Thousand USD -98.54%
2016 48.63 Million USD 1.93%
2015 47.71 Million USD 6.66%
2014 44.73 Million USD 69.02%
2013 26.46 Million USD -0.71%
2012 26.65 Million USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD -100.0%
2008 4.83 Million USD -60.07%
2007 12.1 Million USD -8.77%
2006 13.26 Million USD 0.0%
2005 - USD -100.0%
2004 26.1 Thousand USD -42.94%
2003 45.75 Thousand USD 218.97%
2002 14.34 Thousand USD 0.0%
2001 - USD 0.0%

Peer Total Debt Comparison of Resverlogix Corp.

Name Total Debt Total Debt Difference
Appili Therapeutics Inc. 8.18 Million CAD 20.695%
Eupraxia Pharmaceuticals Inc. 13.78 Million CAD 52.902%
Helix BioPharma Corp. - CAD -Infinity%
Microbix Biosystems Inc. 6.64 Million CAD 2.322%
Medicenna Therapeutics Corp. - CAD -Infinity%
Satellos Bioscience Inc. - CAD -Infinity%
Oncolytics Biotech Inc. 423 Thousand CAD -1434.515%
Sernova Corp. 136.12 Thousand CAD -4668.481%